Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

MarketScreener
marketscreener.com > news > otsuka-arm-s-lung-cancer-drug-plus-chemotherapy-trial-shows-six-month-median-pfs-benefit-ce785bdcd88cf32d

Otsuka Arm's Lung Cancer Drug Plus Chemotherapy Trial Shows Six-Month Median PFS Benefit

7+ hour, 38+ min ago   (41+ words) marketscreener.com Otsuka Holdings Co., Ltd. Otsuka Arm's Lung Cancer Drug Plus Chemotherapy Trial Shows Six-Month Median PFS Benefit Published on 09/14/2026 at 01:08 am EDT...

Moomoo
moomoo.com > news > post > 76/19/6667 > from-trillion-dollar-computing-power-to-the-new-generation-blockbuster

From Trillion-Dollar Computing Power to the???New Generation Blockbuster Drug???: Value Differentiation and Capacity Realization in NVIDIA???s AI for Science Ecosystem

7+ hour, 45+ min ago   (22+ words) From Trillion-Dollar Computing Power to the “New Generation Blockbuster Drug”: Value Differentiation and Capacity Realization in NVIDIA’s AI for Science Ecosystem Moomoo...

@pharma_indian
indianpharmapost.com > people > c-prasanna-kumar-reddy-appointed-assistant-general-manager-ard-at-msn-laboratories-21826

C. Prasanna Kumar Reddy appointed Assistant General Manager – AR&D at MSN Laboratories

9+ hour, 8+ min ago   (213+ words) C. Prasanna Kumar Reddy has been appointed Assistant General Manager – Analytical Research & Development (AR&D) at MSN Laboratories’ R&D Center, bringing more than 19 years of experience in analytical research, pharmaceutical R&D and laboratory operations. Over the course of his…...

Asian Business Review
asianbusinessreview.com > commentary > eastward-shift-in-biotech-world-why-india-and-china-could-lead-next-wave

The eastward shift in the biotech world: Why India and China could lead the next wave

11+ hour, 46+ min ago   (747+ words) China’s advantage is scale across discovery and development, and India in cost-efficiency and innovation footprint. For decades, the global biotechnology map was largely defined by a handful of established centres in the United States, and Europe. Boston, the Bay Area,…...

Todayville Edmonton
todayville.com > edmonton > medicine-should-be-done-with-the-patient-not-to-the-patient

Medicine Should Be Done With the Patient, Not To the Patient

1+ day, 8+ hour ago   (1474+ words) Modern oncology has made real progress: some cancers that were once fatal can now be cured or controlled for years, with surgery, radiation, chemotherapy, and newer targeted and immune therapies playing a part. But oncology has also become highly specialized,…...

Mid-day
mid-day.com-day.com

Researchers test CAR T cells to treat difficult rheumatoid arthritis

9+ hour, 17+ min ago   (173+ words) CAR T-cell therapy tested for rheumatoid arthritis to eliminate disease-driving B cells Mid-Day CAR T-cell therapy tested for rheumatoid arthritis to eliminate disease-driving B cells 14 September,2026 08:59 AM IST | Berlin | Agencies Inflammatory foci (magenta) are no longer detectable after the therapy....

Google News
marketscreener.com > news > astrazeneca-s-phase-3-trial-of-combination-treatment-for-breast-cancer-fails-to-meet-primary-endpoin-ce785bdcd88bf227

AstraZeneca's Phase 3 Trial of Combination Treatment for Breast Cancer Fails to Meet Primary Endpoint

9+ hour, 22+ min ago   (48+ words) Published on 09/13/2026 at 11:24 pm EDT AstraZeneca: Share price weakness of late, should be capitalised on September 04, 2026 at 08:13 am EDT AstraZeneca Is Said to Have Explored Bristol Myers Merger Heading for a major healthcare merger between AstraZeneca and Bristol-Myers Squibb?...

MarketScreener
marketscreener.com > news > hengrui-pharmaceuticals-lung-cancer-drug-included-in-china-s-breakthrough-therapy-designation-list-ce785bdcd888fe24

Hengrui Pharmaceuticals' Lung Cancer Drug Included in China's Breakthrough Therapy Designation List

10+ hour ago   (69+ words) marketscreener.com Every day, we give you free access to essential global business and financial news, through the work of our journalists and our partnerships with leading news and data providers. Jiangsu Hengrui Pharmaceuticals Co.,Ltd Hengrui Pharmaceuticals' Lung Cancer…...

JournalArta
journalarta.com > en > 09/14/2026 > astrazeneca-stock-drops-0-43-today-momentum-weakens

AstraZeneca Stock Drops 0.43%: Full Details — JournalArta Global

10+ hour, 25+ min ago   (318+ words) On September 14, 2026: price 11,708.00 GBp, trend sideways, RSI 41.1, support 11,460.00, resistance 12,476.00. technical analysis of astrazeneca stock. The momentum picture is mixed, and that is what makes this name interesting right now. The RSI at 41.1 is neutral, so the stock is neither overbought…...

PharmaDispatch
pharmadispatch.com > news > fda-clears-telixs-pixclara-as-the-worlds-first-approved-brain-cancer-imaging-drug

FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug

10+ hour, 18+ min ago   (124+ words) PharmaDispatch FDA clears Telix's Pixclara as the world's first approved brain cancer imaging drug Telix Pharmaceuticals has secured landmark approval from the United States Food and Drug Administration for Pixclara, making it the first FDA-sanctioned imaging agent for glioma, the…...